Literature DB >> 8392611

Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope.

S Lombardi1, C Garzelli, C La Rosa, L Zaccaro, S Specter, G Malvaldi, F Tozzini, F Esposito, M Bendinelli.   

Abstract

Synthetic peptides have been used to map linear B-cell epitopes of the third variable (V3) region of the feline immunodeficiency virus (FIV) external membrane glycoprotein gp120. The analysis of sera from naturally and experimentally FIV-infected cats by Pepscan and enzyme immunoassay with four partially overlapping peptides evidenced three antibody-binding domains, two of which mapped in the carboxyl-terminal half of V3. In particular, the V3.3 sequence (Gly-392-Phe-413) turned out to be important for in vitro neutralization of the virus in that the peptide inhibited the FIV-neutralizing activity of pooled immune cat sera, and on the other hand, cat sera raised against this peptide effectively neutralized FIV infectivity for Crandell feline kidney cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392611      PMCID: PMC237860     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Detection of salivary antibodies in cats infected with feline immunodeficiency virus.

Authors:  A Poli; C Giannelli; M Pistello; L Zaccaro; D Pieracci; M Bendinelli; G Malvaldi
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

2.  Comparison of two host cell range variants of feline immunodeficiency virus.

Authors:  T R Phillips; R L Talbott; C Lamont; S Muir; K Lovelace; J H Elder
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.

Authors:  M E White-Scharf; B J Potts; L M Smith; K A Sokolowski; J R Rusche; S Silver
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

4.  Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.

Authors:  R J Grimaila; B A Fuller; P D Rennert; M B Nelson; M L Hammarskjöld; B Potts; M Murray; S D Putney; G Gray
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

5.  Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120.

Authors:  S Karwowska; M K Gorny; A Buchbinder; V Gianakakos; C Williams; T Fuerst; S Zolla-Pazner
Journal:  AIDS Res Hum Retroviruses       Date:  1992-06       Impact factor: 2.205

6.  Simple in vitro methods for titrating feline immunodeficiency virus (FIV) and FIV neutralizing antibodies.

Authors:  F Tozzini; D Matteucci; P Bandecchi; F Baldinotti; A Poli; M Pistello; K H Siebelink; L Ceccherini-Nelli; M Bendinelli
Journal:  J Virol Methods       Date:  1992-06       Impact factor: 2.014

7.  Structure and variations of feline immunodeficiency virus envelope glycoproteins.

Authors:  G Pancino; I Fossati; C Chappey; S Castelot; B Hurtrel; A Moraillon; D Klatzmann; P Sonigo
Journal:  Virology       Date:  1993-02       Impact factor: 3.616

8.  Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus.

Authors:  J K Yamamoto; T Hohdatsu; R A Olmsted; R Pu; H Louie; H A Zochlinski; V Acevedo; H M Johnson; G A Soulds; M B Gardner
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

9.  Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.

Authors:  E O Freed; D J Myers; R Risser
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.

Authors:  M K Gorny; A J Conley; S Karwowska; A Buchbinder; J Y Xu; E A Emini; S Koenig; S Zolla-Pazner
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more
  30 in total

1.  Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.

Authors:  M J Hosie; T Dunsford; D Klein; B J Willett; C Cannon; R Osborne; J Macdonald; N Spibey; N Mackay; O Jarrett; J C Neil
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

2.  Conservation of human immunodeficiency virus type 1 gp120 inner-domain sequences in lentivirus and type A and B retrovirus envelope surface glycoproteins.

Authors:  I Hötzel; W P Cheevers
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.

Authors:  J N Flynn; C A Cannon; J C Neil; O Jarrett
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 4.  Uses of flow cytometry in virology.

Authors:  J J McSharry
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

Review 5.  Feline immunodeficiency virus model for designing HIV/AIDS vaccines.

Authors:  Janet K Yamamoto; Missa P Sanou; Jeffrey R Abbott; James K Coleman
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

6.  A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.

Authors:  S Lombardi; C Garzelli; M Pistello; C Massi; D Matteucci; F Baldinotti; G Cammarota; L da Prato; P Bandecchi; F Tozzini
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain.

Authors:  J N Flynn; C A Cannon; G Reid; M A Rigby; J C Neil; O Jarrett
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

Review 8.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

Review 9.  Lentivirus-induced immune dysregulation.

Authors:  Mary B Tompkins; Wayne A Tompkins
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

10.  Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system.

Authors:  F Baldinotti; D Matteucci; P Mazzetti; C Giannelli; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.